Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.76 |
| ▸ | MTOR | P42345 | 15/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.61 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631514 | 0.94 | MTOR (0.75) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19629362 | 0.93 | MTOR (0.69) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19457633 | 0.89 | MTOR (0.69) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19460915 | 0.89 | MTOR (0.69) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19479130 | 0.89 | MTOR (0.69) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19460657 | 0.88 | MTOR (0.66) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19457723 | 0.88 | MTOR (0.66) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19460574 | 0.87 | MTOR (0.65) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL19460996 | 0.87 | MTOR (0.65) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL10327728 | 0.87 | MTOR (1.00) | PIK3CAMTORPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2021-11-25 | — | — | US | disclosed |
| US-10993947-B2 | Treatment of skin lesions | TORQUR (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | TORQUR AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361665-A1 | TREATMENT OF SKIN LESIONS | CXCR3, C3AR1, CCR3 | PIK3CA 3770/4885MTOR 4061/4885PIK3CB 4445/4885 |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3CB 12/4885 |
| US-20210107913-A1 | TREATMENT OF SKIN DISORDERS | RXFP3, CBR3, CXCR3 | PIK3CA 3974/4885MTOR 2897/4885PIK3CB 4533/4885 |
| US-20220135551-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | PIK3CA 4513/4885MTOR 4473/4885PIK3CB 4670/4885 |
| US-10993947-B2 | Treatment of skin lesions | CXCR3, CCR3, C3AR1 | PIK3CA 3971/4885MTOR 4107/4885PIK3CB 4669/4885 |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3CB 12/4885 |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3CB 12/4885 |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3CB 12/4885 |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM1, CHRM2, C1R | PIK3CA 4513/4885MTOR 4473/4885PIK3CB 4670/4885 |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | CXCR3, CCR3, C3AR1 | PIK3CA 3971/4885MTOR 4107/4885PIK3CB 4669/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | PIK3CA 1/4885MTOR 2/4885PIK3CB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.